Open Access. Powered by Scholars. Published by Universities.®
Cell and Developmental Biology Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Cell and Developmental Biology
Ofatumumab For Post-Transplant Lymphoproliferative Disorder, Madhav Seshadri, Genevieve M. Crane, Usama Gergis
Ofatumumab For Post-Transplant Lymphoproliferative Disorder, Madhav Seshadri, Genevieve M. Crane, Usama Gergis
Hematology/Oncology and Stem Cell Therapy
Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with EpsteineBarr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.